Your session is about to expire
What is Duzallo
AllopurinolThe Generic name of this drug
Treatment SummaryGout is an inflammatory condition caused by the accumulation of monosodium urate crystals in the body, especially around joints. It has been known since ancient times and has been documented in medical records and biographies. Allopurinol is a common medication used to reduce urate levels and treat chronic gout. It was approved by the FDA in 1966 and is now made by several different companies.
Zyloprimis the brand name
Duzallo Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zyloprim
Allopurinol
1966
270
Approved as Treatment by the FDA
Allopurinol, also called Zyloprim, is approved by the FDA for 12 uses such as Secondary gout and Primary Gout .Secondary gout
Primary Gout
Chemotherapy
Malignant Lymphomas
Symptomatic
Hyperuricemia
Leukemias
Gouty Arthritis
Used to treat Gouty Arthritis in combination with Lesinurad
failed previous allopurinol monotherapy
Used to treat failed previous allopurinol monotherapy in combination with Lesinurad
Recurrent calcium oxalate calculi
female patients with daily uric acid excretion that exceeds 750 mg/day
male patients with daily uric acid excretion that exceeds 800 mg/day
Effectiveness
How Duzallo Affects PatientsAllopurinol works by reducing the amount of uric acid the body makes. This helps to relieve the symptoms of gout such as painful swelling, joint pain, redness, and difficulty moving.
How Duzallo works in the bodyAllopurinol helps reduce gout symptoms by blocking an enzyme that converts hypoxanthine to xanthine and xanthine to uric acid. This drug also increases the amount of hypoxanthine and xanthine for nucleotide and nucleic acid synthesis. As a result, uric acid levels in the urine and blood drop, which reduces the risk of gout symptoms. Allopurinol also encourages the dissolution of existing gout tophi by lowering the amount of uric acid in the blood below its solubility limit. Although hypoxanthine and xanthine levels increase after allop
When to interrupt dosage
The recommended dosage of Duzallo is contingent upon the diagnosed condition, including Gout Flares, Leukemias and Cancer. The amount of dosage is contingent on the method of delivery (e.g. Injection, powder, lyophilized, for solution - Intravenous or Tablet, film coated - Oral) provided in the following table.Condition
Dosage
Administration
Hyperuricemia
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Chemotherapy
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Eczema
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Chronic Kidney Disease (CKD)
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Lesch-Nyhan Syndrome
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Leukemias
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Gouty Arthritis
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Metabolic Diseases
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Symptomatic
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Malignant Lymphomas
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Gout Flares
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Primary Gout
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Recurrent calcium oxalate calculi
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
female patients with daily uric acid excretion that exceeds 750 mg/day
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Secondary gout
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
male patients with daily uric acid excretion that exceeds 800 mg/day
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Urinary Bladder Calculi (disorder)
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
failed previous allopurinol monotherapy
, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Injection, powder, lyophilized, for solution, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral
Warnings
There are 20 known major drug interactions with Duzallo.Common Duzallo Drug Interactions
Drug Name
Risk Level
Description
Didanosine
Major
The serum concentration of Didanosine can be increased when it is combined with Allopurinol.
Oteracil
Major
The therapeutic efficacy of Oteracil can be decreased when used in combination with Allopurinol.
Pegloticase
Major
The risk or severity of adverse effects can be increased when Allopurinol is combined with Pegloticase.
Abacavir
Minor
Allopurinol may decrease the excretion rate of Abacavir which could result in a higher serum level.
Aclidinium
Minor
Allopurinol may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Duzallo Toxicity & Overdose RiskThe lowest toxic dose for rats is 10 mg/kg, while the lowest toxic dose for mice is 78 mg/kg. Reproductive studies on rats and rabbits have not shown any adverse effects, but there have been reports of increased numbers of dead fetuses and malformations in pregnant mice given 50 or 100 mg/kg allopurinol. Nursing women should be cautious while taking allopurinol as it has been found in the milk of a nursing mother. Studies have not found allopurinol to be mutagenic or carcinogenic.
Duzallo Novel Uses: Which Conditions Have a Clinical Trial Featuring Duzallo?
560 active clinical trials are investigating the potential of Duzallo to mitigate Kidney Disease, Chemotherapy-related complications and Metabolic Diseases.Condition
Clinical Trials
Trial Phases
Chronic Kidney Disease (CKD)
246 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 1, Phase 4, Early Phase 1
Eczema
25 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Phase 4, Early Phase 1, Phase 3
Leukemias
0 Actively Recruiting
Secondary gout
0 Actively Recruiting
Hyperuricemia
2 Actively Recruiting
Phase 2, Phase 3
failed previous allopurinol monotherapy
0 Actively Recruiting
Gout Flares
0 Actively Recruiting
Gouty Arthritis
1 Actively Recruiting
Phase 2, Phase 3
Urinary Bladder Calculi (disorder)
0 Actively Recruiting
Primary Gout
0 Actively Recruiting
Malignant Lymphomas
3 Actively Recruiting
Phase 1
Recurrent calcium oxalate calculi
0 Actively Recruiting
Metabolic Diseases
3 Actively Recruiting
Phase 1, Phase 2, Not Applicable
Lesch-Nyhan Syndrome
0 Actively Recruiting
male patients with daily uric acid excretion that exceeds 800 mg/day
0 Actively Recruiting
Chemotherapy
2 Actively Recruiting
Not Applicable
female patients with daily uric acid excretion that exceeds 750 mg/day
0 Actively Recruiting
Symptomatic
0 Actively Recruiting
Duzallo Reviews: What are patients saying about Duzallo?
3.7Patient Review
10/21/2018 I experienced a lot of side effects with this medication.
Patient Q&A Section about duzallo
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What does allopurinol do?
"This medication is used to lower the level of uric acid in your blood. Uric acid build-up can cause tiny, sharp crystals to form in and around your joints, which is a condition known as gout. Kidney stones can also be caused by too much uric acid. Allopurinol is used to prevent these conditions from occurring or to lessen their symptoms."
Answered by AI
Why was lesinurad discontinued?
"- The FDA has announced the discontinuation of Ironwood Pharmaceuticals' Duzallo (lesinurad/allopurinol) and Zurampic (lesinurad). This is due to business reasons and not because of any safety, efficacy or quality issues."
Answered by AI
What is Duzallo used for?
"Duzallo is a medication used to lower uric acid levels in adults with gout. It is typically given when allopurinol alone has not been effective."
Answered by AI